SCHEMBL3756558

SCHEMBL3756558

CN(C)C1CCN(c2nc3ccc(NC(=O)/C=C\c4ccc5ccccc5c4)cc3s2)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.43
MCHR1 Q99705 9/20 0.42
HCAR2 Q8TDS4 1/20 0.41
NPC1 O15118 1/20 0.40
CASP3 P42574 1/20 0.40
RAB9A P51151 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
KCNH2 Q12809 1/20 0.40
TP53 P04637 2/20 0.39
PIN1 Q13526 3/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
CASP1 P29466 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13054108 1.00 MAPT (0.43) MAPTMCHR1HCAR2NPC1CASP3
SCHEMBL3756561 1.00 MAPT (0.43) MAPTMCHR1HCAR2NPC1CASP3
SCHEMBL3750065 0.92 MAPT (0.47) MAPTMCHR1NPC1CASP3RAB9A
SCHEMBL13054106 0.92 MAPT (0.47) MAPTMCHR1NPC1CASP3RAB9A
SCHEMBL3750062 0.92 MAPT (0.47) MAPTMCHR1NPC1CASP3RAB9A
SCHEMBL3754936 0.89 MAPT (0.55) MAPTMCHR1NPC1CASP3RAB9A
SCHEMBL13054094 0.89 MAPT (0.55) MAPTMCHR1NPC1CASP3RAB9A
SCHEMBL3754940 0.89 MAPT (0.55) MAPTMCHR1NPC1CASP3RAB9A
SCHEMBL3756405 0.89 MAPT (0.56) MAPTMCHR1KCNH2TP53LMNA
SCHEMBL3744471 0.89 MAPT (0.43) MAPTMCHR1NPC1CASP3RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7838543-B2 Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles ELI LILLY AND COMPANY (US) 2010-11-23 US disclosed
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-07-02 US disclosed
EP-1828177-B1 NOVEL MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R MAPT 1507/4885MCHR1 1/4885HCAR2 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.